Neuroanatomical Mapping of s100 Immunoreactivity Reviewed

LMG Campos1,2,*, L. Pinato1, CSG Spilla1, AL Decanini1, IZ Vieira1, MY Hamasaki1 and MI Nogueira1

1Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil
2Department of Speech-Language and Hearing Therapy, São Paulo State University, Marília, SP, Brazil

Abstract

S100B is a small calcium-binding protein expressed primarily by astrocytes involved in several pathologies. Several studies have shown S100B protein immunoreactivity (S100B-IR) in brain specific areas, and some of them showed the cells identity under physiological and/or pathological conditions. This review reports the S100B-IR distribution in the brain specific areas of different adult mammals and complement with our results in order to provide a complete overview about the S100B-IR and cell identity. This review highlights a heterogeneous distribution of S100B-IR in prosencephalic, diencephalic, brainstem and cerebellum areas. Regarding cellular identity, the co-localization of S100B-IR and GFAP-IR occurred predominantly in periventricular areas, in the hippocampus and the septal area in contrast with cortical regions. In addition, cells S100B-IR but not GFAP-IR were also found in these areas. The analysis throughout the rostro-caudal axis of the brain showed that S100B-IR did not present colocalization with neurons (NeuN-IR). This complete description can be potentially used for researches that aim to consider changes in S100B expression in different pathologies.

Keywords: Biomarker; Rats; Calcium-binding protein; Immunohistochemistry; Mapping; Astrocytes

Introduction

S100B is a calcium-binding protein produced and released constitutively mainly by astrocytes, and like other S100 proteins it interacts with several effector proteins exerting intra and extracellular actions.

Many hypotheses have been formulated concerning the biological role(s) of this protein found in soluble form in intracellular membranes, centrosomes, microtubules and type III intermediate filaments [1,2]. Although the cellular production of S100B is primarily involved in the modulation of the intracellular milieu, S100B is also secreted in a regulated manner, and it is possible to detect it both in brain tissue or in bodily fluids [3,4].

Most S100B studies have been performed in bodily fluids of humans in pathological conditions or in animal pathological models since increased levels of S100B have been positively correlated with brain pathological conditions [5]. For example, S100B was examined in the CSF (cerebrospinal fluid) and serum of adult patients with acute cerebral infarction, meningitis, multiple sclerosis, dementia, and others neurological pathologies [6-10].

Most S100B studies have been performed in bodily fluids of humans in pathological conditions or in animal pathological models since increased levels of S100B have been positively correlated with brain pathological conditions [5]. For example, S100B was examined in the CSF (cerebrospinal fluid) and serum of adult patients with acute cerebral infarction, meningitis, multiple sclerosis, dementia, and others neurological pathologies [6-10].

Most S100B studies have been performed in bodily fluids of humans in pathological conditions or in animal pathological models since increased levels of S100B have been positively correlated with brain pathological conditions [5]. For example, S100B was examined in the CSF (cerebrospinal fluid) and serum of adult patients with acute cerebral infarction, meningitis, multiple sclerosis, dementia, and others neurological pathologies [6-10].

In the central nervous system (CNS), the immunoreactivity (IR) of this protein has been found in astrocytes, oligodendrocytes, Bergman and ependymal cells types. Regarding to the presence of S100B-IR in neurons, results in our lab showed a lack of colocalization of S100B in mature neurons in the rat brain (Figure 1), in contrast to (adult) human brain [11].

Looking for elucidate the role of this protein, several studies in the literature have shown S100B expression in specific areas, and some mapped the identity and distribution of the expressing this protein in the brain under physiological and pathological conditions. In this review we summarize and discuss the main findings on S100B distribution along the brain rostrocaudal axis and its strict cell localization described in the literature and with data of our laboratory.

During normal physiological conditions, S100B acts changing calcium levels to regulate the activity of target proteins which are related to normal cellular function [2], besides a neurotrophic role during brain development [12].

It has been shown that this protein affects neuronal electrical discharge activity by modulating potassium currents at very low concentrations [13].

Figure 1: Different shapes of S100B-IR cells in brain coronal sections of adult male rats. The expression of S100B along the rostrocaudal axis revealed cells that had different cellular morphology. Bright-field photomicrographs showing the different shapes of S100B-IR cells. (a1) and (a2): S100B-IR Bergman cells that have an irregular shape, (b1): S100B-IR ependymal cell that have a rounded shape, (c1): S100B-IR astrocytes that have an oval shape, (c2): S100B-IR astrocytes that have few cytoplasmatic ramifications. (a), (b), and (c): Nissl staining. Scale bars, 100 μm in (a1), (a2), (b1), (b2), (c1) and (c2); 20 μm in (a), (b) and (c).

*Corresponding author: Leila Maria Guissoni Campos, Department of Speech-Language and Hearing Therapy, São Paulo State University, Av. Hygino Muzzi Filho, 737 Bairro: Mirante 17.525-000 - Marília, SP, Brazil, Tel: 55-14-3402-1324; E-mail: leilacampos@usp.br

Received October 27, 2015; Accepted November 18, 2015; Published November 25, 2015

Citation: Campos LMG, Pinato L, Spilla CSG, Decanini AL, Vieira IZ (2015) Neuroanatomical Mapping of s100 Immunoreactivity Reviewed. J Neurol Neurophysiol 6: 326. doi:10.4172/2155-9562.1000326

Copyright: © 2015 Campos LMG, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The expression pattern of S100B could be representative of its function in the maintenance of Ca2+ homeostasis, energy metabolism, cellular structure, regulation of intracellular signal transduction, cell cycle, as well as synaptic plasticity as observed in memory and learning studies [1,2,14,15,16].

As a matter of fact there is a S100B expression in the hippocampus under basal conditions (Figure 2, Table 1) and also an evidence of daily and developmental homestatic variations in the hippocampus of male and female rats [17]. This region was characterized by a dense distribution of S100B-IR cells throughout the rostrocaudal axis (Figure 2 d1, e1) that were colocalized with GFAP-IR, mainly in the hippocampus’fimbria (Figure 3C2, Table. 2). These findings are consistent with suggestions that S100B could be important to hippocampal neuroplasticity [18-23].

It must be pointed that beside S100B present a high colocalization with GFAP in the periventricular area, hippocampal formation and in the septal area there are some S100B-IR cells that do not express GFAP mainly in the cortex (Figure 3 A2, B2; Figure 4, Table 2). These cells had an irregular shape, and the whole cell body was stained, although the immunoreactivity is stronger in the cytoplasm than in processes (Figure 5 c1 and c2).

In the telencephalon, a greater amount of S100B immunolabeling was observed in the frontal cortex compared to the other lobes (Figure 2 a1, Table 1) in physiological [11,24] and pathological [25] conditions. Oval-shaped cells with few ramifications were labeled specifically in the region of the medial orbital cortex and area 1 and 2 of the cingulate.
This labeling was found predominantly in the rostral portions and was markedly decreased moving in the caudal direction. The exception was the visual cortex that showed high expression of S100B [26,27]. In physiological condition [11,24] it was also shown that S100B at low doses stimulates astrocyte cell line proliferation [19]. On the other hand, in pathological conditions [25] S100B at higher concentrations stimulates nitric oxide synthase (iNOS) activity and increase the mRNA levels of this enzyme in rat cortical astrocytes via activation of NF-κB [28].

In the corpus callosum (medial surface of the telencephalon): higher S100B-IR was observed in the genu (anterior portion) (Figure 5C c2; Figure 2 b1, Table 1), when compared to the splenium (posterior portion). The S100B-IR cells, similar to those of the cortex, showed an oval shape with few branches (Figure 5C c2).

In the septal region (medial surface of the telencephalon): S100B-IR cells were detected in the dorsal, medial and ventral septal nuclei.
Mapping of cells expressing S100B protein in the brain under physiological conditions.

| Brain Region                          | Data from our study | Gos et al., 2013 | Steiner et al., 2007 | Dyck et al., 1993; Müller, 1992 | Boyes et al., 1986 |
|---------------------------------------|---------------------|------------------|----------------------|---------------------------------|-------------------|
| TeLencephalon                         | +                   | +                | +                    | +                               | +                 |
| Frontal cortex                        | +                   | +                | +                    | +                               | +                 |
| Medial orbital cortex                 | +                   | +                | +                    | +                               | +                 |
| Cingulate cortex, area 1              | +                   | +                | +                    | +                               | +                 |
| Cingulate cortex, area 2              | +                   | +                | +                    | +                               | +                 |
| Prelimbic cortex                     | +                   | +                | +                    | +                               | +                 |
| Infralimbic cortex                   | +                   | +                | +                    | +                               | +                 |
| Secondary motor cortex               | +                   | +                | +                    | +                               | +                 |
| Primary motor cortex                 | +                   | +                | +                    | +                               | +                 |
| Visual cortex                        | +                   | +                | +                    | +                               | +                 |
| Corpus callosum                      | +                   | +                | +                    | +                               | +                 |
| Anterior comm.                       | -                   | +                | +                    | +                               | +                 |
| Septal area                          | +                   | +                | +                    | +                               | +                 |
| Lateral septal nu, dorsal part       | +                   | +                | +                    | +                               | +                 |
| Lateral septal nu, dorsal part intermedia | +       | +                | +                    | +                               | +                 |
| Lateral septal nu, dorsal part ventral | +                   | +                | +                    | +                               | +                 |
| Fornix                               | -                   | +                | +                    | +                               | +                 |
| Hippocampus                          | +                   | +                | +                    | +                               | +                 |
| Dentate gyrus (CA4)                  | +                   | +                | +                    | +                               | +                 |
| Hippocampus (CA1, CA2, CA3)         | +                   | +                | +                    | +                               | +                 |
| Subiculum                            | +                   | +                | +                    | +                               | +                 |
| Fimbria of hippocampus               | +                   | +                | +                    | +                               | +                 |
| Basal Nuclei                         | +                   | +                | +                    | +                               | +                 |
| Caudate                              | +                   | +                | +                    | +                               | +                 |
| Putamen                              | +                   | +                | +                    | +                               | +                 |
| Globus pallidus                      | +                   | +                | +                    | +                               | +                 |
| Claustrum                            | +                   | +                | +                    | +                               | +                 |
| Amygdala                             |                      |                  | +                    | +                               | +                 |
| lateral amygd nu, dorsolateral       | -                   |                  | +                    | +                               | +                 |
| lateral amygd nu, ventromedial       | +                   |                  | +                    | +                               | +                 |
| Posteromed cortical amygd nu         | +                   |                  | +                    | +                               | +                 |
| Diencephalon                         | +                   | +                | +                    | +                               | +                 |
| Thalamus                             | +                   | +                | +                    | +                               | +                 |
| Paraventricular thalamic nu          | +                   | +                | +                    | +                               | +                 |
| Paraventricular th nu, posterior     | +                   | +                | +                    | +                               | +                 |
| Stria medullaris of thalamus         | -                   |                  | +                    | +                               | +                 |
| Epithalamus                          | +                   | +                | +                    | +                               | +                 |
| Lateral habenular nu                 | +                   | +                | +                    | +                               | +                 |
| Medial habenular nu                  | +                   | +                | +                    | +                               | +                 |
| Habenular comm                       | +                   | +                | +                    | +                               | +                 |
| Subthalamus                          | -                   | +                | +                    | +                               | +                 |
| Zona incerta                         | -                   | +                | +                    | +                               | +                 |
| Hypothalamus                         | +                   | +                | +                    | +                               | +                 |
| Medial preoptic area                 | +                   | +                | +                    | +                               | +                 |
| Supraoptic nu                        | -                   |                  | +                    | +                               | +                 |
| Periventricular hypothamic nu        | -                   |                  | +                    | +                               | +                 |
| Subparaventricular zone of hi       | -                   |                  | +                    | +                               | +                 |
| Anterior hypoth area posterior       | -                   |                  | +                    | +                               | +                 |
| Ventromedial hy nu, ant              | -                   |                  | +                    | +                               | +                 |
| Ventromed nu, dorsomed               | -                   |                  | +                    | +                               | +                 |
| Ventromed hypoth nu, cent            | -                   |                  | +                    | +                               | +                 |
| Ventromed nu, ventrolat              | -                   |                  | +                    | +                               | +                 |
| Premammillary nu, dorsal             | -                   |                  | +                    | +                               | +                 |
| Premammillary nu, medial             | -                   |                  | +                    | +                               | +                 |

Citation: Campos LMG, Pinato L, Spilla CSG, Decanini AL, Vieira IZ (2015) Neuroanatomical Mapping of s100 Immunoreactivity Reviewed. J Neurol Neurophysiol 6: 326. doi:10.4172/2155-9562.1000326
Citation: Campos LMG, Pinato L, Spilla CSG, Decanini AL, Vieira IZ (2015) Neuroanatomical Mapping of s100 Immunoreactivity Reviewed. J Neurol Neurophysiol 6: 326. doi:10.4172/2155-9562.1000326

throughout the rostrocaudal axis (Figure 2 c1), mainly in the dorsal portion and periventricular regions.

In the basal nuclei: weak S100B-IR was observed in the claustrum mainly close to the insular cortex and in the corpus striatum. Similarly, weak S100B-IR as observed in putamen, head of the caudate nucleus, in the caudal portions of the globus pallidus and throughout the areas adjacent to the lateral ventricles.

In the amygdaloid complex: weak S100B-IR was observed throughout the medial ventroposterior amygdaloid nucleus and in the rostral portion of the globus pallidus and throughout the areas adjacent to the lateral ventricles.

In the Brainstem, S100B-IR cells were detected in ependymal cells in the caudal portion of the fourth ventricle (Figure 3 B2 – asterisk) and colocalized with GFAP-IR in periventricular cells (Figure 3 A2, B2; Figure 4b). In pyramids and in the nucleus raphe pallidus S100B-IR cells were observed along the rostrocaudal axis. The nucleus tractus solitarius also had S100B-IR cells in the rostral portion of the gracile tubercles.

In the Cerebellum, S100B-IR cells were observed mainly in Bergman cells around Purkinje neurons (Figure 5 a1, a2) which are consistent with previous results that showed S100B-IR in this specialized type of astrocyte [29]. Additionally, there was colocalization of S100B with GFAP in the granular layer (Figure 3 D2).

S100B in Pathological Conditions

In pathological conditions, secretion of S100B from astrocytes is stimulated by metabolic stress (oxygen, serum and glucose deprivation) and is suppressed by glutamate [30,31]. Once released, S100B can affect neurons, primarily by engagement of RAGE (Receptor for Advanced Glycation End Products), its primary receptor [32]. Then, depending on the intracellular calcium concentration, it exerts either a trophic (nanomolar) or destructive (micromolar levels) effect on neurons when can lead to cellular lesions or death [18,19,33,34].
A role in heterogeneously distribution of S100B Protein

In this review we observed that S100B-IR in physiological condition is heterogeneously distributed in the brain and in different cell types with more pronounced expression in areas such as the cerebral cortex and cerebellum, hippocampus and periventricular areas. Its physiologic role in these areas should be examined in future.

The expression of S100B protein is known to be colocalized with GFAP, which is highly expressed in astrocytes [37]. This review showed that the astrocytes GFAP-IR of periventricular areas exhibit a large amount of co-localization with S100B-IR. In these situations, S100B-IR is primarily located in the astrocytes cytoplasm, while GFAP-IR is expressed primarily in astrocytes extensions [38,39]. This distribution could indicate a homeostatic role of S100B in glial cells that involves ventricular areas. Similarly co-localization of S100B with ependymal cells, suggests that in the CNS, cells other than astrocytes can secrete this protein into the CSF. In chronic neuropathologies (e.g., in Parkinson’s disease), S100B protein levels in the CSF are increased. This high expression of S100B in periventricular areas probably reflects the role of these areas in detecting the health condition and in turn reflexly regulating S100B levels in the CSF [40].

In contrast to the periventricular areas, GFAP-IR and S100B-IR colocalization in astrocytes was lower in cortical areas maybe because of its state of activation since GFAP is a marker for activated astrocytes [41,42]. Thus, one possible hypothesis is that under normal conditions, astrocytes in the periventricular areas remain more active than in the cerebral cortex.

Astrocytes are the most common glial cells in the CNS, and they feature a heterogeneous group that has distinct functions such as the regulation of metabolism and control of glucose by modulating neuronal release of neuroactive substances and the control of neurotransmitter in the synaptic cleft [38,43].

Conclusion

S100B exerts intracellular and extracellular actions that are not completely clarified. Despite it is possible to detect it either in brain tissue or in bodily fluids, most studies of S100B have been performed in bodily fluids of humans in pathological conditions or in animal pathological models. Increased levels of S100B in fluids have been positively correlated with brain pathological conditions like cerebral infarction, meningitis, multiple sclerosis and dementia.

Identity of cells expressing this protein in the brain under physiological conditions and in pathological conditions showed that this protein is presented in astrocytes, oligodendrocytes, Bergman and ependymal cells in both conditions. In physiological conditions there is a high but not total co-localization of S100B and GFAP in the periventricular areas, hippocampus and in the septal area. On the other hand, cortical regions are highlighted predominantly by S100B-IR astrocytes that not express GFAP.

Regarding the brain mapping in physiological conditions, the more pronounced S100B expression was in areas such as the cortex cerebral and cerebellum, hippocampus and periventricular areas. All main areas of telencephalon, corpus callosum, Septal area, Hippocampal, Basal Nuclei, almost all parts of Amygdala and Thalamus, Epithalamus, periventricular hypothamic nucleus, periaqueductual gray. Substantia nigra and cerebellum Granulosa layer express S100B-IR.

Anterior commissure, Subthalamus, Zona incerta, almost all Hypothalamic nuclei, almost all brainstem nuclei, cerebellum...
molecular layer do not express S100B-IR in physiological conditions. The Substantia nigra was the only area analyzed until this moment that shows co-localization of S100B-IR and GFAP-IR in pathological diseases. The high expression of S100B in periventricular areas could be due to these areas sensing the state of health and regulating S100B levels in the CSF.

This complete description can be potentially used for researches that aim to consider changes in S100B expression in different pathologies.

Acknowledgments

This work was supported by Fundação de Amparo a Pesquisa de São Paulo (FAPESP), and LMGC is graduate fellow of Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).

References

1. Donato R (2003) Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 60: 540-551.
2. Donato R, Sorci G, Riuzzi F, Arcuri C, Bianchi R, et al. (2009) S100B’s double life: intracellular regulator and extracellular signal. Biochim Biophys Acta 1793: 1008-1022.
3. Gonçalves CA, Leite MC, Nardini P (2008) Biological and methodological features of the measurement of S100B, a putative marker of brain injury. Clin Biochem 41: 755-763.
4. Al-Ayadhi LY, Mostafa GA (2012) A lack of association between elevated serum levels of S100B protein and autoimmune in autistic children: J Neurolinflammation 9: 54.
5. Kleindienst A, Ross Bullock M (2006) A critical analysis of the role of the neurotrophic protein S100B in acute brain injury. J Neurotrauma 23: 1185-1200.
6. Infante JR, Martínez A, Ochoa J, Cañadas F, Torres-Avisbal M, et al. (2003) Cerebrospinal fluid S-100 protein levels in neurological pathologies. J Physiol Biochem 59: 255-261.
7. Portela L, Bremen JC, Walz R, Bianchini M, Tort AB, et al. (2002) Serum S100B levels in patients with lupus erythematosus: preliminary observation. Clin Diagn Lab Immunol 9: 164-166.
8. Storoni M, Verbeek MM, Illes Z, Mariginer R, Teunissen CE, et al. (2012) Serum GFAP levels in optic neuropathies. J Neurol Sci 317: 289-295.
9. Steinacker P, Weidemaa K, Cepek L, Feneberg E, Kretzschmar HA, et al. (2013) GFAP levels in optic neuropathies. J Neurol Sci 317: 117-122.
10. Al-Ayadhi LY, Mostafa GA (2012) A lack of association between elevated serum levels of S100B protein and autoimmune in autistic children: J Neurolinflammation 9: 54.
11. Kleindienst A, Ross Bullock M (2006) A critical analysis of the role of the neurotrophic protein S100B in acute brain injury. J Neurotrauma 23: 1185-1200.
12. Infante JR, Martínez A, Ochoa J, Cañadas F, Torres-Avisbal M, et al. (2003) Cerebrospinal fluid S-100 protein levels in neurological pathologies. J Physiol Biochem 59: 255-261.
13. Portela L, Bremen JC, Walz R, Bianchini M, Tort AB, et al. (2002) Serum S100B levels in patients with lupus erythematosus: preliminary observation. Clin Diagn Lab Immunol 9: 164-166.
14. Storoni M, Verbeek MM, Illes Z, Mariginer R, Teunissen CE, et al. (2012) Serum GFAP levels in optic neuropathies. J Neurol Sci 317: 289-295.
15. Steinacker P, Weidema K, Cepek L, Feneberg E, Kretzschmar HA, et al. (2013) GFAP levels in optic neuropathies. J Neurol Sci 317: 117-122.
16. Al-Ayadhi LY, Mostafa GA (2012) A lack of association between elevated serum levels of S100B protein and autoimmune in autistic children: J Neurolinflammation 9: 54.
17. Kleindienst A, Ross Bullock M (2006) A critical analysis of the role of the neurotrophic protein S100B in acute brain injury. J Neurotrauma 23: 1185-1200.
astrocytes: implications for its role in the propagation of reactive gliosis. J Neurochem 131: 190-205.

42. Farfara D, Lifshitz V, Frenkel D (2008) Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer’s disease. J Cell Mol Med 12: 762-780.

43. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates, 4th edn. Academic Press, San Diego, CA.